JP2013510091A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510091A5
JP2013510091A5 JP2012537218A JP2012537218A JP2013510091A5 JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5 JP 2012537218 A JP2012537218 A JP 2012537218A JP 2012537218 A JP2012537218 A JP 2012537218A JP 2013510091 A5 JP2013510091 A5 JP 2013510091A5
Authority
JP
Japan
Prior art keywords
virus
cells
particle
polypeptide
respiratory syncytial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537218A
Other languages
English (en)
Japanese (ja)
Other versions
JP5917402B2 (ja
JP2013510091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/055334 external-priority patent/WO2011056899A2/en
Publication of JP2013510091A publication Critical patent/JP2013510091A/ja
Publication of JP2013510091A5 publication Critical patent/JP2013510091A5/ja
Application granted granted Critical
Publication of JP5917402B2 publication Critical patent/JP5917402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012537218A 2009-11-03 2010-11-03 キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ Expired - Fee Related JP5917402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25776609P 2009-11-03 2009-11-03
US61/257,766 2009-11-03
PCT/US2010/055334 WO2011056899A2 (en) 2009-11-03 2010-11-03 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps

Publications (3)

Publication Number Publication Date
JP2013510091A JP2013510091A (ja) 2013-03-21
JP2013510091A5 true JP2013510091A5 (cg-RX-API-DMAC10.html) 2013-12-19
JP5917402B2 JP5917402B2 (ja) 2016-05-11

Family

ID=43970730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537218A Expired - Fee Related JP5917402B2 (ja) 2009-11-03 2010-11-03 キメラＲＳＶ−Ｆポリペプチド、およびレンチウイルスＧａｇまたはアルファレトロウイルスＧａｇに基づくＶＬＰ

Country Status (5)

Country Link
US (1) US8920812B2 (cg-RX-API-DMAC10.html)
EP (1) EP2496609A4 (cg-RX-API-DMAC10.html)
JP (1) JP5917402B2 (cg-RX-API-DMAC10.html)
CN (1) CN102753582A (cg-RX-API-DMAC10.html)
WO (1) WO2011056899A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
EP2636413A1 (en) * 2012-03-09 2013-09-11 Ecole Normale Superieure De Lyon Chimeric virus-like particles (VLP) containing functional hMPV proteins
JP5845376B2 (ja) * 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
JP2015527296A (ja) * 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
CN104450631A (zh) * 2014-11-11 2015-03-25 中国人民解放军第四军医大学 肠道病毒ev71型vp1基因病毒样颗粒及其制备方法和应用
MX2019000725A (es) 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗
WO2019183228A1 (en) * 2018-03-21 2019-09-26 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
WO2020092365A1 (en) 2018-10-29 2020-05-07 Binh Ha Rsv virus-like particles and methods of use thereof
JP2023519837A (ja) 2020-03-30 2023-05-15 ヴァリエーション バイオテクノロジーズ インコーポレイテッド コロナウイルスを処置するためのワクチン組成物
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
GB202212472D0 (en) * 2022-08-26 2022-10-12 Ip2Ipo Innovations Ltd Retroviral vectors
WO2024082281A1 (en) * 2022-10-21 2024-04-25 Nanjing Haiwei Pharmaceutical Technologies Co., Ltd. Novel formulations of epinephrine and uses thereof
WO2024254544A2 (en) * 2023-06-07 2024-12-12 Nvelop Therapeutics, Inc. Compositions and methods for promoting payload delivery in cells
CN117777314B (zh) * 2024-02-26 2024-05-14 赛德特生物制药有限公司 慢病毒载体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69735376T2 (de) 1996-11-26 2006-12-14 Stressgen Biotechnologies Corp., Victoria Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
BRPI0112276B8 (pt) 2000-06-23 2021-05-25 The Government Of The Us Secretary Of Department Of Health And Human Services vírus sincicial respiratório (rsv) recombinante infeccioso e polinucleotídeo isolado contendo um genoma ou antigenoma de resv recombinante parcial ou completo
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
WO2002090549A2 (en) 2001-03-12 2002-11-14 Proteologics Inc. Compositions and methods for the modulation of viral maturation
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
CN1325512C (zh) 2002-05-16 2007-07-11 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
US20060088909A1 (en) 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
GB0226722D0 (en) 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
EP2044198A4 (en) * 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
DE102006060799A1 (de) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101668857A (zh) 2007-02-21 2010-03-10 诺瓦瓦克斯股份有限公司 嵌合的新城疫病毒vlp

Similar Documents

Publication Publication Date Title
US20230023093A1 (en) Dna antibody constructs and method of using same
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
US20220112273A1 (en) DNA Antibody Constructs And Method Of Using Same
US10087240B2 (en) DNA antibody constructs and method of using same
US12054537B2 (en) Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
KR102604877B1 (ko) 감염성 질환의 예방 및/또는 치료와 종양학적 질환의 치료를 위한 약독화된 인플루엔자 벡터
JP2010528601A5 (cg-RX-API-DMAC10.html)
JP2012526839A5 (cg-RX-API-DMAC10.html)
CA3085627C (en) Ebola virus and marburg virus glycoprotein mucin-like domain replacement expression system used as new vaccine approaches
Pandey et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
RU2013103335A (ru) Конструкции гомодимерных белков
WO2022192594A2 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
Di Vincenzo Determinants of the Antibody Response against HIV Env induced by Nanoparticle Vaccination and Intrastructural Help
CN117043182A (zh) 经修饰的抗病毒结合剂
TW202246317A (zh) 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
Macdonald Lentiviral vector vaccines for T cell-mediated protection against influenza
Seth et al. Development of Indian HIV-1 Subtype C Vaccine Candidates